Fang Ting-Chun, Tsai Yu-Shan, Chang Ming-Hong
Department of Neurology, Taichung Veterans General Hospital, Neurological Institute, Taichung, Taiwan.
Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
Front Aging Neurosci. 2023 Jul 18;15:1213977. doi: 10.3389/fnagi.2023.1213977. eCollection 2023.
Hyposmia is a common prodrome in patients with Parkinson's disease (PD). This study investigates whether olfactory changes in PD differ according to the degree of olfactory dysfunction and whether there are changes in motor and non-motor symptoms.
The 129 subjects with PD were divided into two groups: anosmia and non-anosmia. All cases were reassessed within 1-3 years after the initial assessment. The assessment included the MDS-Unified PD Rating Scale (MDS-UPDRS), the University of Pennsylvania Smell Identification Test (UPSIT), Beck's Depression Inventory-II (BDI-II), Montreal Cognitive Assessment (MoCA), and equivalence dose of daily levodopa (LEDD). The generalized estimating equation (GEE) model with an exchangeable correlation structure was used to analyze the change in baseline and follow-up tracking and the disparity in change between these two groups.
The anosmia group was older and had a longer disease duration than the non-anosmia group. There was a significant decrease in UPSIT after follow-up in the non-anosmia group (β = -3.62, < 0.001) and a significant difference in the change between the two groups (group-by-time effect, β = 4.03, < 0.001). In the third part of the UPDRS motor scores, there was a tendency to increase the score in the non-anosmia group compared to the anosmia group (group-by-time effect, β = -4.2, < 0.038). There was no significant difference in the group-by-time effect for UPDRS total score, LEDD, BDI-II, and MoCA scores.
In conclusion, this study found that olfactory sensation may still regress in PD with a shorter disease course without anosmia, but it remains stable in the anosmia group. Such a decline in olfaction may not be related to cognitive status but may be associated with motor progression.
嗅觉减退是帕金森病(PD)患者常见的前驱症状。本研究调查了PD患者的嗅觉变化是否因嗅觉功能障碍程度而异,以及运动和非运动症状是否有变化。
129例PD患者被分为两组:嗅觉丧失组和非嗅觉丧失组。所有病例在初次评估后1至3年内进行重新评估。评估包括MDS统一PD评定量表(MDS-UPDRS)、宾夕法尼亚大学嗅觉识别测试(UPSIT)、贝克抑郁量表第二版(BDI-II)、蒙特利尔认知评估(MoCA)以及左旋多巴每日等效剂量(LEDD)。采用具有可交换相关结构的广义估计方程(GEE)模型分析基线和随访追踪的变化以及两组之间变化的差异。
嗅觉丧失组比非嗅觉丧失组年龄更大,病程更长。非嗅觉丧失组随访后UPSIT显著下降(β = -3.62,<0.001),两组之间的变化有显著差异(组×时间效应,β = 4.03,<0.001)。在UPDRS运动评分的第三部分,与嗅觉丧失组相比,非嗅觉丧失组有得分增加的趋势(组×时间效应,β = -4.2,<0.038)。UPDRS总分、LEDD、BDI-II和MoCA评分的组×时间效应无显著差异。
总之,本研究发现,在病程较短且无嗅觉丧失的PD患者中,嗅觉仍可能减退,但在嗅觉丧失组中保持稳定。这种嗅觉减退可能与认知状态无关,但可能与运动进展有关。